

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)
41145-1001

Application Number
09/642,236

Applicant(s)
GEORGE R. SCHWARTZ

Filing Date
August 17, 2000

Group Art Unit
46

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CMK		H. Heuer et al. "Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats." J. Comp. Neurol 2000 Dec 11; 428(2): 319-36. <i>abstract</i>
		Dept. of Physiology, Univ. of Mich. Med. Sch. "Thyroid hormone in neural rescue." Thyroid 1997 Feb; 7(1): 115-24. <i>abstract</i>
CMK		K. Nakanishi et al. "Thrombopoietin expression in normal and hypobaric hypoxia-induced thrombocytopenic rats." Laboratory Investigation, June, 1999; 79(6): 679-88. <i>abstract</i>

EXAMINER

Chmif

DATE CONSIDERED

3/29/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
41145-1001

SERIAL NO
09/642,236

NOV 21 2000

Information Disclosure
Statement by Applicant

APPLICANT
GEORGE R. SCHWARTZ

TECH CENTER 1600/2900

(Use several sheets if necessary)

FILING DATE
August 17, 2000

GROUP
1646

U.S. PATENT DOCUMENTS


Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
CMK	5,795,569	08/18/98	Bartley et al.	424	85.1	
CMK	5,879,673	03/09/99	Thomas	424	85.1	
CMK	5,980,885	11/09/99	Weiss et al.	424	93.21	
CMK	5,989,537	11/23/99	Holly et al.	424	85.1	

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

CMK	✓	McMorris et al. "Regulation of Oligodendrocyte Development and CNS Myelination by Growth Factors: Prospects for Therapy of Demyelinating Disease." Brain Pathology 6: 313-329 (1996).
CMK	✓	Rogister et al. "Oligodendrocytes: From Development to Demyelinated Lesion Repair." Acta. Neurol. Belg. 1999: 32-39. 99: 32-39, (1999)
CMK		Franklin et al. "Remyelination in the CNS of the hypothyroid rat." NeuroReport 7: 1526-1530 (1996).
CMK	✓	Hinks et al. "Distinctive Patterns of PDGF-A, FGF-2, IGF-1 and TGF-β1 Gene Expression during Remyelination of Experimentally-Induced Spinal Cord Demyelination." Molecular and Cellular Neuroscience 14: 153-168 (1999).
CMK	✓	Calver et al. "Oligodendrocyte Population Dynamics and the Role of PDGF in Vivo." Neuron 20: 869-882 (1998).
CMK	✓	Rodriguez-Peña. "Oligodendrocyte Development and Thyroid Hormone." Instituto J. Investigaciones Biomédicas 4: 497-512 (1999). Neurobiol. 40: 497-512
CMK	✓	Li et al. "Thrombopoietin and its Alternatively Spliced Form are Expressed in Human Amygdala and Hippocampus." Blood 87(12): 5382-4 (1996).
CMK	✓	Souyri. "Mpl: From an Acute Myeloproliferative Virus to the Isolation of the Long Sought Thrombopoietin." Seminars in Hematology 35(3): 222-231 (1998).
CMK		Dubois-Dalcq et al. "Why are growth factors important in oligodendrocyte physiology?" Pathologic Biologie 48: 80-86 (2000).
CMK	✓	Grinspan et al. "Protein Growth Factors as Potential Therapies for Central Nervous System Demyelinating Disorders." Annals of Neurology 36: 5140-5142 (Supplement), (1994).
CMK	✓	Vadhan-Raj. "Recombinant Human Thrombopoietin: Clinical Experience and In Vivo Biology." Seminars in Hematology 35(3): 261-268 (1998).

Examiner




Date Considered

3/28/01

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE Information Disclosure Statement by Applicant (Use several sheets if necessary)	ATTY. DOCKET NO. 41145-1001	SERIAL NO. 09/642,236
	APPLICANT GEORGE R. SCHWARTZ	
	FILING DATE August 17, 2000	GROUP 1646

**OTHER DOCUMENTS CONT'D**

(Including Author, Title, Date, Pertinent Pages, Etc.)

CMK	✓	Barres et al. "Cell Death and Control of Cell Survival in the Oligodendrocyte Lineage." Cell 70: 31-46 (1992).
CMK	✓	McMorris et al. "Regulation of Oligodendrocyte Development and Central Nervous System Myelination by Insulin-like Growth Factors." Ann. NY. Acad. Sci. 692: 321-34 (1993).
CMK		Herndon. "The Effect of Drugs on Oligodendrocyte Proliferation and Myelin Regeneration." Progress in Brain Research 71: 485-491 (1987).
CMK	✓	Somlo et al. "Recombinant Human Thrombopoietin in Combination with Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy." Blood 93(9): 2788-2806 (1999).
CMK	✓	Cohen et al. "Cyclic AMP Regulates PDGF-Stimulated Signal Transduction and Differentiation of an Immortalized Optic-Nerve-Derived Cell Line." The Journal of Experimental Biology 202: 461-473 (1999).
CMK	✓	Fruttiger et al. "Defective Oligodendrocyte Development and Sever Hypomyelination in PDGF-A Knockout Mice." Development 126: 457-467 (1999).
CMK		Fressinaud et al. "Platelet-Derived Growth Factor Partly Prevents Chemically Induced Oligodendrocyte Death and Improves Myelin-Like Membranes Repair In Vitro." GLIA 16: 40-50 (1996).
CMK	✓	Matsas et al. "The Functional Roles of Glial Cells in Health and Disease: Dialogue Between Glia and Neurons," <i>Advances in Experimental Medicine and Biology</i> Chapter 15. (1999)
CMK	✓	Metcalf et al. "Thyrotropin-Releasing Hormone." Ann. NY Acad. Sci. 553: 422-430 (1989).

Examiner <i>Chmifer</i>	Date Considered 3/28/01
----------------------------	----------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.